Onconetix (ONCO) Announces 1:85 Reverse Share Split
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Oil surge keeps S&P 500, Nasdaq in check before earnings; Salesforce lifts Dow
- Oil prices rise 2% as attacks on Saudi Arabia overshadow Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
- One dead in new attack on Saudi airport, a day after Houthi strike kills 13
- Bausch + Lomb names Appio interim CEO as Saunders departs
- Cerebras Systems hits new 52-week low on unlock concerns
- Stryker invests $400M in CMR Surgical with option to acquire
- Lumentum shares fall after hitting 52-week high
Onconetix, Inc. Announces 1-for-85 Reverse Stock Split and Results of the Special Meeting of Stockholders
June 11, 2025 11:30 AM EDTCINCINNATI, Ohio, June 11, 2025 (GLOBE NEWSWIRE) -- Onconetix, Inc. (NASDAQ: ONCO) (Onconetix or the Company), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for mens health and oncology, today announced that the Companys stockholders have approved a proposal to effect a reverse split, which was voted on at the Companys 2025 special meeting of stockholders (the Special Meeting) held on May 30, 2025, and that its Board of Directors (the Board of Directors or Board) approved a 1-for-85 reverse stock split of its outstanding shares of common stock, to be... More



